Overview
Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer
Status:
Completed
Completed
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with donor peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of pentostatin followed by peripheral stem cell transplantation in treating patients who have advanced kidney cancer.Phase:
Phase 1/Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Jonsson Comprehensive Cancer CenterCollaborator:
National Cancer Institute (NCI)Treatments:
Cyclosporine
Cyclosporins
Pentostatin
Criteria
DISEASE CHARACTERISTICS:- Histologically confirmed advanced renal cell cancer
- No bone metastases
- No CNS disease
- Must have an allogeneic donor available
PATIENT CHARACTERISTICS:
Age:
- Over 18
Performance status:
- ECOG 0-1
Life expectancy:
- 3 to 6 months
Hematopoietic:
- Hemoglobin at least 10 g/dL
- Complete blood count normal
Hepatic:
- Bilirubin no greater than 3 times upper limit of normal (ULN)
- Transaminases no greater than 4 times ULN
- No evidence of portal hypertension
Renal:
- Creatinine no greater than 2.0 mg/dL
- No uncontrolled hypercalcemia
Cardiovascular:
- No New York Heart Association class 3 or 4 heart disease
Pulmonary:
- DLCO at least 40% of predicted
Other:
- No severe functional neurological impairment
- HIV negative
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- No more than 1 prior biologic therapy
Chemotherapy:
- No more than 6 months of prior chemotherapy
Endocrine therapy:
- At least 1 year since prior steroids
Radiotherapy:
- Not specified
Surgery:
- Not specified